clinical trial · NCT03888612
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Prostate Cancer MetastaticARV-110
brief summary
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
started
Mar 1, 2019
primary completion
Apr 29, 2024
completion
Jan 27, 2025
last updated
Apr 1, 2025
official title
A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol